Page 11 - Research Models News Today

North Growth Management Ltd. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 15.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,000 shares of the medical research company’s stock after purchasing an additional 5,000 shares during the […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) saw a large decrease in short interest in November. As of November 30th, there was short interest totalling 1,470,000 shares, a decrease of 9.8% from the November 15th total of 1,630,000 shares. Based on an average trading volume of 532,900 shares, the short-interest ratio is […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price target raised by Citigroup from $190.00 to $215.00 in a report issued on Monday morning, Benzinga reports. They currently have a neutral rating on the medical research company’s stock. Other analysts have also issued research reports about the company. Evercore ISI decreased their price […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year […]

Frontier Capital Management Co. LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 1.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,336 shares of the medical research company’s stock after selling 279 shares during the […]

Woodley Farra Manion Portfolio Management Inc. boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,058 shares of the medical research company’s stock after purchasing an additional 2,253 shares […]

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 0.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,633 shares of the medical research company’s stock after […]

Covestor Ltd grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 259.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219 shares of the medical research company’s stock after purchasing an additional 158 shares during the […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) COO Birgit Girshick acquired 1,322 shares of the company’s stock in a transaction on Monday, November 20th. The shares were bought at an average cost of $187.82 per share, with a total value of $248,298.04. Following the acquisition, the chief operating officer now directly owns […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average […]